-

12:46:50 AM

NNVC Stock News

NNVC - NanoViricides Inc

05/31/23 6:40 AM

AMEX : NNVC

conferenceslow float

NanoViricides, Inc. to Present at the BIO International Convention in Boston on June 5th, 2023 at 3:15pm ET

SHELTON, CT / ACCESSWIRE / May 31, 2023 / NanoViricides, Inc. (NYSE Amer:NNVC) (the "Company"), announces that the Company's President, Dr. Anil Diwan, will be presenting a talk in person at the BIO International Convention in Boston on June 5th, 2023 at 3:15pm ET.EventBIO International

RHEA-AI

very positive

05/16/23 6:45 AM

AMEX : NNVC

clinical trialcovid-19low float

NanoViricides Has Filed its Quarterly Report - Clinical Trials of Broad-Spectrum COVID Drug About to Begin

SHELTON, CT / ACCESSWIRE / May 16, 2023 / NanoViricides, Inc. (NYSE Amer:NNVC) (the "Company"), reports that it has filed its Quarterly Report on Form 10-Q for the fiscal third quarter ending March 31, 2023 with the Securities and Exchange Commission (SEC) on Monday, May 15, 2023. The

RHEA-AI

neutral

05/04/23 6:45 AM

AMEX : NNVC

conferenceslow float

NanoViricides, Inc. to Present at The Inaugural Ef Hutton Global Conference on May 10, 2023 in New York City

NanoViricides, Inc. (NYSE American: NNVC ) (the “Company”), a clinical stage global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, announces that Anil R. Diwan, Ph.D.,

RHEA-AI

positive

04/25/23 6:45 AM

AMEX : NNVC

covid-19low float

NanoViricides is Expanding its Broad-Spectrum Antiviral Program to Explore Further Antiviral Applications of its COVID Clinical Drug Ingredient

NanoViricides, Inc. (NYSE American: NNVC) (the "Company"), a clinical stage global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, reports that it is exploring additional antiviral applications

RHEA-AI

neutral

04/17/23 6:45 AM

AMEX : NNVC

clinical trialcovid-19low float

NanoViricides Has Shipped Drug Products for Impending Clinical Trials of NV-CoV-2, Its COVID Drug Candidate

NanoViricides, Inc. (NYSE American: NNVC) (the "Company"), a clinical stage global leader in nanomedicines against viruses, announced today that it has shipped the drug products for impending clinical trials of NV-CoV-2, its COVID drug candidate, to its

RHEA-AI

neutral

04/04/23 7:45 AM

AMEX : NNVC

covid-19low float

NanoViricides Signs a License Agreement That Includes Clinical Evaluation of Its COVID-19 Drug Candidates

NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a global leader in nanomedicines against viruses, announced today that it has executed a License Agreement with Karveer Meditech Pvt. Ltd., Kolhapur, India ("Karveer"). Under this Agreement, Karveer

RHEA-AI

neutral

02/15/23 6:30 AM

AMEX : NNVC

clinical triallow float

NanoViricides Has Filed its Quarterly Report - Company has Begun Production of Coronavirus Drug for Clinical Trials

NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that it has filed its Quarterly Report on Form 10-Q for the fiscal first quarter ending December 31, 2022 with the Securities and Exchange Commission (SEC) on Tuesday, February 14, 2023.

RHEA-AI

neutral

01/04/23 6:35 AM

AMEX : NNVC

conferenceslow float

NanoViricides, Inc. to Present at the Biotech Showcase(TM) 2023 Conference in San Fransisco on January 9th at 10:30am PT

NanoViricides, Inc. (NYSE Amer.: NNVC) (the "Company"), announces that the Company's President, Dr. Anil Diwan, will be presenting a talk in person at the Biotech Showcase™ 2023 Conference in San Fransisco on Monday, January 9th at 10:30pm PT. Event

RHEA-AI

neutral

12/05/22 6:45 AM

AMEX : NNVC

conferenceslow float

NanoViricides, Inc. to Present at the RHK Capital Disruptive Growth Conference in New York City on December 6th at 1:20pm ET

NanoViricides, Inc. (NYSE Amer. NNVC) (the "Company"), announces that the Company's President, Dr. Anil Diwan, will be presenting a talk at the RHK Capital Disruptive Growth Conference in New York City on December 6th at 1:20pm ET. The presentation will

RHEA-AI

neutral

11/15/22 6:45 AM

AMEX : NNVC

low float

NanoViricides, Inc. Has Filed its Quarterly Report: Coronavirus Drug NV-CoV-2 IND Stage

NanoViricides, Inc. (NYSE American: NNVC) (the "Company"), reports that it has filed its Quarterly Report on Form 10-Q for the fiscal first quarter ending September 30, 2022 with the Securities and Exchange Commission (SEC) on Monday, November 14,

RHEA-AI

neutral

NNVC Data

IndustryResearch and Development in Biotechnology
Websitenanoviricides.com
Security nameNanoViricides Inc
Issue typecs
SectorProfessional, Scientific, and Technical Services
Sic code8731
Employees17
Tags
- Health Technology
- Biotechnology
Address1 Controls Dr
StateConnecticut
CityShelton
Zip06484-6153
CountryUS
Phone12039376137

About NanoViricides Inc

nanoviricides, inc., a nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. its products pipeline includes herpecide dermal topical and eye drops for the treatment of shingles, phn, chickenpox, herpes, recurrent herpes labialis, genital herpes, and ocular herpes keratitis; and herpecide intraocular injection for viral acute retinal necrosis. the company also develops flucide broad-spectrum anti-influenza nanoviricide, which is injectable for hospitalized patients and oral for outpatients; nanoviricide eye drops for viral diseases of the external eye; denguecide for treatment of all types of dengue viruses; and hivcide that is an escape-resistant anti-hiv nanoviricide. in addition, it is also involved in research and development of other nanoviricides drug projects for treatment of different viruses and indications; and herpecide program expansion drug projects for different herpes viruses for different indications. nanovir